Literature DB >> 22574971

Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.

Charles Butler1, Daynna J Wolff, Yubin Kang, Robert K Stuart, Luciano J Costa.   

Abstract

We utilized a cohort with a high frequency of young patients to explore the correlation between fluorescence in situ hybridization (FISH) detected chromosomal abnormalities (CA) and age in multiple myeloma (MM). One hundred and nineteen patients with MM were included in the analysis. The median age was 60 years, 51% of patients were female and 56% were Caucasian. Translocations involving the IGH gene on chromosome 14 were more likely to be detected in older (≥ 60 years) patients (32.8% vs. 15.5%, p = 0.03), particularly because of a higher frequency of t(4;14) (14.8% vs. 3.4%, p = 0.05). Myeloma cells from older patients were also three times more likely to have multiple CA. The presence of high-risk CA influenced survival in patients <60 but not in patients ≥ 60. Among standard-risk patients, survival was significantly superior for patients <60. No effect of age on survival was detected for high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574971     DOI: 10.3109/10428194.2012.691483

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.

Authors:  Dong Wook Jekarl; Chang-Ki Min; Ahlm Kwon; Hyunjung Kim; Hyojin Chae; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

2.  Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Authors:  Pratibha S Kadam Amare; Hemani Jain; Shraddha Nikalje; Manju Sengar; Hari Menon; Nitin Inamdar; P G Subramanian; Sumeet Gujral; Tanuja Shet; Sridhar Epari; Reena Nair
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.